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Abstract Tremendous growth in opioid prescribing over two
decades in the USA has correlated with proportional increases
in diversion, addiction, and overdose deaths. Pseudoaddiction,
a concept coined in 1989, has frequently been cited to indicate
that under-treatment of pain, rather than addiction, is the more
pressing and authentic clinical problem in opioid-seeking pa-
tients. This investigative review searched Medline articles
containing the term Bpseudoaddiction^ to determine its foot-
print in the literature with a focus on how it has been charac-
terized and empirically validated. By 2014, pseudoaddiction
was discussed in 224 articles. Only 18 of these articles con-
tributed to or questioned pseudoaddiction from an anecdotal
or theoretical standpoint, and none empirically tested or con-
firmed its existence. Twelve of these articles, including all four
that acknowledged pharmaceutical funding, were proponents
of pseudoaddiction. These papers described pseudoaddiction
as an iatrogenic disease resulting fromwithholding opioids for
pain that can be diagnosed, prevented, and treated with more
aggressive opioid treatment. In contrast, six articles, none with
pharmaceutical support, questioned pseudoaddiction as a clin-
ical construct. Empirical evidence supporting pseudoaddiction
as a diagnosis distinct from addiction has not emerged.
Nevertheless, the term has been accepted and proliferated in
the literature as a justification for opioid therapy for non-
terminal pain in patients who may appear to be addicted but
should not, from the perspective of pseudoaddiction, be diag-
nosed with addiction. Future studies should examine whether
acceptance of pseudoaddiction has complicated accurate pain
assessment and treatment, and whether it has contributed to or
reflected medical-cultural shifts that produced the iatrogenic
opioid addiction epidemic.
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Introduction
Over the last 20 years, US health care has undergone a major
shift in attitudes and clinical practice involving increased pre-
scribing of opioids to patients with different causes and levels
of acute and chronic pain. This shift has been attributed to
various trends and organizational initiatives within health care
that have (1) increased the prioritization and emphasis on the
diagnosis of pain, relative to other medical issues (e.g., Bpain
is the fifth vital sign^) [1], and (2) the treatment of pain with
opioid analgesics as opposed to other modalities that have
reputations of being less clinically efficacious and/or less
cost-effective than opioids [2•]. Accordingly, massive in-
creases in US expenditures for prescription pharmaceuticals
(from $12 billion in 1980 to $263 billion in 2011 [3]) have
been driven in part by increases in opioid prescriptions and
consumption [4–9]. From 2000 to 2009, opioids dispensed
from US outpatient pharmacies rose from 174.1 million to
256.9 million doses [10]. By the end of the last decade,
Americans, although just 4 % of the world’s population, were
consuming 80 % of the global opioid supply and 99 % of the
world’s hydrocodone supply [9, 11].
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While the origins of these trends are attributable to the recog-
nition of pain as a significant, undertreated public health prob-
lem [12–15], a growing emphasis on opioids as the major, front-
line treatment of choice for pain has gone hand in hand with
reducing physicians’ fears of opioids causing or contributing to
addiction [16, 17]. Pseudoaddiction, the subject of this review, is
a clinical concept that has been influential as a diagnosis in
clinical practice and the medical literature to indicate that
under-treatment of pain, rather than risk of addiction with opi-
oids, should be the primary clinical concern. Pseudoaddiction
(with Bpseudo-^ from Latin meaning Bfake,^ Bnot real,^ www.
Merriam-Webster.com) was originally introduced and defined
by Weissman and Haddox in 1989 as an Biatrogenic syndrome
that mimics the behavioral symptoms of addiction^ in patients
receiving inadequate doses of opioids for pain [18].
Unfortunately, in the quarter century after the introduction
of pseudoaddiction, sharp rises in the utilization and supply of
opioids via prescribers in the USA have been paralleled by
rises in negative outcomes, including abuse and diversion,
emergency department encounters, addictions, and fatal over-
doses [6, 8, 9, 19•, 20]. For example, as emergency department
visits related to opioid overdoses increased from 144,655 in
2004, to 366,181 in 2011 [21], their fatal outcomes quadrupled
from 4030 in 1999, to 16,651 in 2010 [22••]. In 2010, not
accounting for any treatment for opioid addiction, US hospital
costs for treating opioid overdoses was four times larger than
for heroin overdoses and totaled nearly $2.3 billion—roughly
double the annual extramural research budget of the National
Institute on Drug Abuse [23••]. In line with this data, the
Centers for Disease Control and Prevention (CDC) and the
Office of National Drug Control Policy (ONDCP) have listed
prescription drug overdoses as an epidemic [24].
The purpose of this review is to describe the scope and
content of the medical literature on pseudoaddiction since its
introduction a quarter century ago. The origins of
pseudoaddiction as a diagnostic construct, its sponsorship
via pharmaceutical industry support, its empirical basis, and
its proponent and opponent arguments are covered. We then
conclude with a discussion of implications of these findings in
terms of the current prescription opioid epidemic, with con-
siderations for future research. This examination is relevant
and timely to the modern prescription opioid epidemic, given
the fact that the vast majority of opioid medications that are
misused and/or diverted to generate addiction and overdoses
do originate as legal prescriptions from doctor’s offices [25,
26]. Prolific over-prescribing of opioids has grown so routine
that, in at least one US state, geographical proximity to med-
ical care and outpatient pharmacies that dispense opioids has
been demonstrated to be a population risk factor for acquiring
addictive disease [19•]. As contextualized by health insurance
reimbursement and medication coverage plans that readily
support opioid prescribing for pain diagnoses, while remain-
ing relatively unsupportive of evidence-based treatments for
addiction diagnoses [2•, 27•], these trends suggest that since
the introduction of pseudoaddiction, health care has shifted
too far in favor of treating pain with opioids. With a new
and broadening consensus that the evidence base does not
support the use of chronic opioids for chronic, non-terminal
pain [4, 5, 15, 17, 28–32, 33••], a literature review of
pseudoaddiction is needed to inform opinions on whether
the construct has been harmful or beneficial to patients, and
whether it should survive or be abandoned.
Origination of Pseudoaddiction
The 1989 introduction of pseudoaddiction happened in the
form a single case report of a 17-year-old man with acute
leukemia, who was hospitalized with pneumonia and chest
wall pain [18]. The patient was initially given 5 mg of intra-
venousmorphine every 4 to 6 h on an as-needed dosing sched-
ule but received additional doses and analgesics over time.
After a few days, the patient started engaging in behaviors that
are frequently associated with opioid addiction, such as
requesting medication prior to scheduled dosing, requesting
specific opioids, and engaging in pain behaviors (e.g.,
moaning, crying, grimacing, and complaining about various
aches and pains) to elicit drug delivery. The authors argued that
this was not idiopathic opioid addiction but pseudoaddiction,
which resulted from medical under-treatment (insufficient opi-
oid dosing, utilization of opioids with inadequate potency, ex-
cessive dosing intervals) of the patient’s pain. In describing
pseudoaddiction as an Biatrogenic^ syndrome, Weissman and
Haddox inverted the traditional usage of iatrogenic as harm
caused by a medical intervention. In pseudoaddiction, iatrogen-
ic harm was described as being caused by withholding treat-
ment (opioids), not by providing it.
Weissman and Haddox proposed that patients who
present with pseudoaddiction go through three phases:
stimulus, escalation, and crisis. In stimulus, at pain onset,
the patient receives inadequate analgesia and requests
more medication, frequently requesting specific drugs by
name. In escalation, the patient realizes that to receive
additional medication, he has to convince a health care
provider of the legitimacy of his or her pain. In crisis,
culminating when unrelieved pain continues, the patient
engages in increasingly bizarre drug-seeking behaviors,
leading to Ba crisis of mistrust^ with anger and isolation
by the patient and frustration and avoidance by the health
care team. The authors concluded that to prevent or treat
pseudoaddiction, the health care team needs to (a) estab-
lish trust, i.e., Bthe patient must have trust that the care-
givers believe the pain is real and that all attempts will be
made towards pain control,^ and (b) provide rational pain
management, i.e., appropriate and timely use of opioids
based on patients’ pain reports.
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Footprint in the Medical Literature
and Pharmaceutical Industry Support
A comprehensive search of the National Library of
Medicine’s bibliographic database/article index (OVID
Medline), to gauge the scope and content of the literature on
pseudoaddiction, was conducted by the authors in November,
2013, entering Bpseudoaddiction^ as the key word. A total of
224 papers were identified. From this collection, 134 were
review articles (including clinical reviews and guidelines, eth-
ical and policy reviews, and position and consensus state-
ments based on reviews), 33 were original studies (i.e., studies
that collected and analyzed primary data), 31 were commen-
taries (including editorials, clinical notes, and chapter intro-
ductions), 10 were case reports, and 16 were categorized as
Bother^ (including reference books, book reviews, abstracts,
posters, and policy statements). Most of the entries (106) ap-
peared in pharmacological, pain, anesthesiology, palliative
care, and oncology journals. The rest were published in
journals encompassing general medicine and related subspe-
cialties (54), nursing (27), addiction and psychiatric journals
(19), psychological/neurological journals (8), and other types
of journals or books, including ethics and policy, health ser-
vices research, nutrition, science, and reference books (10).
Further examination of this set of 224 papers classified
them according to whether they were (1) studies that
attempted to empirically validate pseudoaddiction as a clinical
concept; (2) articles that examined the concept critically
and added new thought to supporting, characterizing, or
refuting the phenomenon; and (3) papers that accepted
pseudoaddiction as a true clinical phenomena or diagnosis by
restating previous definitions or providing explanations or ex-
amples without adding new knew knowledge or perspectives
on it. Of the 224 articles, none exist that attempted to empir-
ically validate the concept of pseudoaddiction (category 1).
Just 18 provided supportive elaboration on the concept and/
or added critical thought (category 2) while 206 papers cite the
concept as a matter of routine acceptance. Among the 18 cat-
egory 2 articles, 12 elaborated on pseudoaddiction as a genu-
ine clinical phenomenon, 4 were in disagreement, and 2 ad-
dressed pseudoaddiction not from a clinical but a social
perspective.
Because pharmaceutical company funding of academic med-
ical publications or authors has been found to be associated with
conclusions favoring those companies’ interests [34], we also
determined if papers or their authors were noted as receiving
pharmaceutical company support. Of the 224 publications, 22
were marked as being sponsored by pharmaceutical companies
or having authors that received pharmaceutical honoraria.
Pharmaceutical companies that provided this support and repre-
sentative opioid products sold by them included the following:
Abbott Laboratories (meperidine, various hydrocodone formu-
lations, hydromorphone), Alpharma (morphine formulations),
ALZA Corporation (fentanyl), Bristol-Meyers Squibb
(oxymorphone formulations), Cephalon, Inc. (fentanyl formula-
tions), Grünenthal GmbH (Tramadol), Janssen-Cilag/Johnson&
Johnson Pharmaceuticals (fentanyl, tapendadol), King
Pharmaceuticals (morphine formulations), Purdue Pharma (oxy-
codone, hydromorphone), and QRx Pty, Ltd. (morphine and
oxycodone formulations). While the original 1989 Weisman
andHaddox paper introducing pseudoaddiction did not list phar-
maceutical support [18], nearly half of the subsequent papers on
pseudoaddiction that did disclose pharmaceutical support (9 of
22) list Purdue Pharma. From the 12 papers that support and
elaborate on pseudoaddiction as a true clinical entity, 4
list pharmaceutical industry support. None of the six
papers that dissented or questioned the construct validity
of pseudoaddiction listed pharmaceutical support.
Proponent Versus Opponent Elaborations
on Pseudoaddiction
Articles Contributing to the Concept of Pseudoaddiction
Most of the 12 articles promoting pseudoaddiction as a true
clinical phenomenon [15, 35–45] stated that aberrant drug-
related behaviors (e.g., drug-seeking and other behaviors sug-
gesting addiction in patients reporting pain) should generally
be interpreted as more likely representing pseudoaddiction
than true addiction, on behalf of ensuring adequate pain treat-
ment. Positive drug screens (for non-treatment opioids or il-
licit substances) and other forms of addiction risk assessment
are suggested to not be reliable proof of addiction, since such
tools are not considered to be capable of adjusting for
pseudoaddiction. This stance is adopted because the na-
ture of the internal motivation for analgesic misuse (and
not objective measurers of drug intake, or aberrant drug
use patterns) is suggested to be the key factor that dis-
tinguishes pseudoaddiction from addiction. Patients reporting
unrelieved pain as their reason for engaging in aberrant drug-
related behaviors are understood as pseudoaddicts, and those
stating they are seeking euphoria are understood as addicts. In
2003, Elander et al. formalized a means to discriminate be-
tween pseudoaddiction versus addiction, in which both syn-
dromes are actually based on the same 12 criteria from the
fourth edition of the Diagnostic and Statistical Manual
(DSM-IV) for substance dependence. The presence of three
or more of the DSM-IV criteria could pinpoint either
pseudoaddiction or drug dependence (i.e., addiction). But, if
the DSM-IV criteria occurred in association with pain or at-
tempts to control pain, they are deemed pseudoaddiction,
hence a reflection of under-treatment of pain. If they occurred
in the absence of pain or involve analgesic use for purposes
other than pain control (e.g., mood-altering effects and eupho-
ria), they indicate true addiction [35].
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To the extent that discerning pseudoaddiction from addic-
tion based exclusively on patient’s subjective reporting of pain
could be problematic, proponents of pseudoaddiction have
espoused an additional means of confirming pseudoaddiction
by addressing the under-treated pain with more opioid anal-
gesics, and observing resolution of problem behaviors [18,
46]. Also, while pseudoaddiction is understood as being dif-
ferent from true addiction, it might, however, lead to true
addiction, if not treated vigorously with opioid analgesics
[43].
Notably, as the opioid epidemic has increased in severity
and scope in recent years, attitudes about pseudoaddiction,
including among authors who have espoused is existence,
have evolved. For example, Passik et al. (2011) indicated that
Buse of the term expanded beyond the scope initially intended,
^ essentially being used to explain too wide a range of aberrant
behaviors, too many types of patients, in too many settings. In
addition, accumulating clinical experience with opioids by
many pain experts had produced the realization that increasing
opioid doses is often not the most effective way to reduce pain
[42].
Articles Refuting Pseudoaddiction
The major theme from the four articles concluding that
pseudoaddiction is not a true clinical phenomenon [47–50]
centered on the criticism that pseudoaddiction remains untest-
ed and uncharacterized as an objectively confirmable diagno-
sis. Instead, pseudoaddiction operates as a Bclinical label with-
out specific therapeutic, predictive, or diagnostic value^
(Chabal et al., 1998) and is used to rationalize problem behav-
iors. These authors pinpoint the difficulty in objectively
assessing motivations for aberrant drug-related behaviors, or
pain, and suggest that behaviors themselves rather than self-
reported motivations for the behaviors should be used as the
key diagnostic information.
Pseudoaddiction as a Social Phenomenon
Two articles espoused the perspective that pseudoaddiction
(and to some extent addiction itself) is best understood as a
social rather than biological construct, in which the label says
more about the judgments and motivation of the diagnostician
(or society) than the patient [51, 52]. The movement to frame
pain management as a human rights issue rests on moral and
clinical judgments about who has pain and who needs or de-
serves opioids. By defining pseudoaddiction (need for pain
treatment) as distinct from addiction (compulsive, harmful
use), there is a separation between Bthe ‘natural’ consequences
of ‘proper’ use of opioid medications by ‘legitimate’ patients^
from those with addiction [51]. The distinction between ad-
diction and pseudoaddiction is viewed as problematic since it
requires differential ethical and clinical responses [52] to
Bseparate out ‘bad’ drug-seeking addicts from ‘good’
undertreated pain patients in the face of behaviors that are
virtually indistinguishable^ [51]. The claim that aberrant
drug-related behaviors in pain patients are caused by the
under-treatment of their condition can be extended to the be-
havior of Baddicts,^ but given that addicts are typically under-
stood as antisocial and criminal, their behavior is viewed as a
sign of their own psychology rather than the result of a partic-
ular social context [52]. In essence, pseudoaddiction is under-
stood as the social judgment of blame on the physician for not
giving opioids to patients when they should, while addiction is
blame put on the patient in wanting opioids when they should
not.
Conclusion
Pseudoaddiction is a quarter-century-old concept that has not
been empirically verified. Although no evidence supports its
existence as a diagnosable clinical entity with objective signs
and specific treatments, the term is widely accepted and pro-
liferated in the medical literature as an Binfluential educational
concept commonly used in pain management lectures^
resulting from the Bremarkable influence^ of one case report
[42]. Nevertheless, supporters of the concept acknowledge
that differentiating pseudoaddiction from true addiction is dif-
ficult since the underlying behaviors in both (drug-seeking)
are indistinguishable. The distinction then is understood as
resting on the idea that pseudoaddiction patients cease aber-
rant drug-related behaviors and opioid misuse after their pain
has been effectively treated [18, 46]. However, even this de-
scription of pseudoaddiction does not ultimately address how
it can be reliably teased apart from addiction since Btrue ad-
dicts^ will refrain from drug-seeking at least temporarily after
receiving opioids, or as in the context of opioid maintenance
treatment (e.g., with methadone) as indicated for opioid
addiction.
The existence of pseudoaddiction, and its distinction from
true addiction, is understood by proponents as being based on
the patient’s reported motivation for pain relief (e.g., if their
behavior results from pain, then they have pseudoaddiction,
not addiction). The reliability of this conceptualization seems
to hinge on the assumption that addiction and pain do not co-
occur (unless one can comprehend the possibility that a patient
can have fake addiction and true addiction at the same time!).
However, it is not the case that pain and addiction are mutually
exclusive conditions, and no clear evidence exists that having
pain protects against the genesis or expression of addiction
[53]. Numerous studies have found high rates of pain and
opioid addiction comorbidity, while a key and nearly universal
symptom of opioid withdrawal, in opioid addiction, is pain [9,
54–60]. The prevalence of addiction associated with long-term
opioid treatment is difficult to assess, and estimates from
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various studies have varied greatly due to differences in study
design, sample size, study duration, inconsistent definitions of
addiction, and professional orientation of the investigators [9,
56]. A comprehensive review by Højsted and Sjøgren (2007)
found that the occurrence of opioid addiction varied from 0 to
50 % in chronic non-malignant pain patients. These authors
suggested that studies relying on DSM-III and IV criteria may
overestimate addiction prevalence due to inclusion of tolerance
and withdrawal in the criteria, which are Bnormal physio-
logic responses that often occur with the persistent use of
certain medications^ [56]. However, Boscarino et al.
(2011) found that prevalence of lifetime opioid use disor-
ders among patients undergoing long-term opioid therapy
was virtually the same regardless of applying DSM-5
criteria (34.9 %) or DSM-IV criteria (35.5 %) [54], even
though the newer DSM-5 criteria do not allow tolerance
and withdrawal to count toward addiction if the patient is
receiving opioids under Bappropriate medical supervi-
sion.^ Furthermore, a recent comprehensive review of
the literature indicates that a history of opioid misuse is
associated with hyperalgesia, suggesting that although
short-term opioids effectively treat pain, long-term opioid
use and/or addiction may actually cause or exacerbate
pain [61•].
Regardless of the validity of pseudoaddiction, pain is a
clinical phenomenon that remains a significant public
health and scientific challenge. For severe, short-term
pain, involving acute disease or injury detectable on phys-
ical exam or other objective testing, opioids have been
widely accepted and empirically confirmed as effective
in controlling pain and providing comfort. The following
question may then be posed: Has the concept of
pseudoaddiction introduced in 1989 made pain treatment
any better or less challenging?
A primary difficulty in measuring pain is its highly subjec-
tive nature that is influenced bymany cultural, situational, and
individual neuropsychological factors [62–64]. Given the
large degree to which pseudoaddiction does not distinguish
itself from addiction, except based on subjective reporting of
pain, and the extent to which opioid addiction is associated
with or may even cause subjective pain, it is unclear how the
application of pseudoaddiction has further enhanced the clin-
ical assessment and management of pain. Clinical applications
of pseudoaddiction may be particularly detrimental in the set-
ting of chronic pain, where chronic opioid therapy has not
been clearly demonstrated to improve functional status or
quality of life measures [65, 66], or to be efficacious enough
to warrant the serious risk of overdose or addiction [28, 30, 31,
33••, 67, 68••, 69]. Even without producing opioid addiction,
pharmacologic tolerance (desensitization of analgesia) and
hyperalgesia (sensitization to pain) are common in chronic
opioid therapy, developing as early as 1 month after starting
opioids [30, 67, 70]. But then, even if pseudoaddiction may be
more appropriately and constructively applied if limited
to the context of severe, acute pain involving an objec-
tively measurable source of pain (e.g., when the risk of
confusing pain with true addictions is minimal), it re-
mains unclear how the construct has clinical utility. In
other words, what is the benefit of labeling acute pain with a
term other than Bpain^ that falsifies, or dismisses the potential
presence of another brain disorder?
Characterizations of pseudoaddiction have also not ad-
dressed the fact that mental illness comorbidity is high among
chronic pain patients, where psychiatric illness is a risk factor
for chronic pain, analgesic abuse, and drug addiction in gen-
eral [27•, 71–75]. Pain and depression frequently co-occur
and, in some patients, may have the same biology [72, 74].
At the same time, depression and other mental illnesses are
also risk factors for opioid dependence and other addictions
[27•, 73, 76], putting those who are depressed, andmore likely
to seek chronic pain treatment, at especially high risk for
analgesic abuse. Patients at high risk for poor outcomes
on chronic opioid analgesics (i.e., those with mental
health and substance use disorders) are actually more
likely to receive high-dose, long-term opioid therapy—a
well-replicated clinical epidemiological observation
termed by Sullivan as Badverse selection^ [68••, 77].
Since pseudoaddiction justifies opioid use in patients
who demonstrate robust drug-seeking behavior with per-
sistent pain complaints (e.g., in patient groups that may
also have high densities of mental illness and addiction
vulnerability), it is possible that clinical practices utilizing the
pseudoaddiction concept may have inadvertently contributed
to adverse selection.
In conclusion, we find no empirical evidence yet exists to
justify a clinical Bdiagnosis^ of pseudoaddiction. The
renaming of pain with a term that essentially means Bfake
addiction^ and serves to dismiss addiction as part of the clin-
ical differential diagnosis is a construct that is conspicuously
and uniquely attached to opioid therapies which are extremely
addictive analgesics, among many other effective, evidence-
based strategies for analgesia that are far less addictive. If
pseudoaddiction is to remain an influential clinical construct
that is taught in medical schools and textbooks, its usage and
clinical acceptance need empirical support, with evidence-
based disambiguation from addiction, and delineation of its
treatment implications. However, to the extent that a diagnosis
of pseudoaddiction relies on a self-report of pain (that is still
essentially not objectively measurable) as the motivation for
drug-seeking, it is not clear how rigorously it can ever be
proven or disproven in human research. Even achieving ob-
jective, reliable modalities for measuring Breal^ pain in human
beings (e.g., via neuroimaging) would not solve the issue
since real pain and addiction can co-occur, and often do co-
occur, in the context of opioid addiction. Instead, future stud-
ies in animals or humans that explore whether the presence of
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pain in general versus certain subtypes of pain (categorized by
source, quality, and duration), occurring premorbid to addic-
tion, are protective against versus predispose to future opioid
addiction, may be a more fruitful approach to empirically
validating pseudoaddiction. Ultimately, conclusions about
the potential benefits or harms produced by the clinical accep-
tance and utilization of pseudoaddiction may require studies
examining how clinical adherence to the construct impacts the
correct identification, prevention, and treatment not only of
pain but opioid addiction, and secondarily quality of life and
mortality outcomes. Research should also examine the extent
to which the concept may serve as a way for some providers to
apply the diagnostic label of pain to legitimize opioid use in
Bgood^ patients and, in some cases, to secure reimbursement
and avoid regulatory scrutiny of opioid treatment in these
patients, so that they do not have to deal with Bbad^ opioid
addicts, for whom opioid maintenance treatment is highly
regulated, time-demanding, stigmatized, and uncovered by
insurance [27•, 51, 52]. Whether the introduction, and subse-
quent proliferation and clinical application of pseudoaddiction
played an unintended if direct role in inciting or propagating
the current prescription opioid epidemic, or whether it
reflected a medical culture that was already adversely chang-
ing to create the epidemic, remains an unanswered question.
Regardless, it is hard to conclude from this review and the
context of the current prescription opioid epidemic that
pseudoaddiction is an objective, evidence-based diagnosis
that has been clinically beneficial to patient lives. Instead, it
may be most beneficial to retire the term and understand pa-
tients as simply having pain, opioid addiction, or very often
both, and designing treatment strategies that best account for
and balance the competing risk-benefit treatment concerns
that these brain conditions imply.
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